StreetInsider.com News Articles

Propanc Biopharma plans Phase 1b trial for cancer drug PRP

Wed, 12 Aug 2026 08:32:26 -0400

Propanc Biopharma, Inc. (Nasdaq: PPCB) issued a scientific comparison of its lead drug candidate PRP against RAS-targeted cancer therapies developed by Revolution Medicines, Inc. (Nasdaq: RVMD) and Erasca, Inc., according to a company press release.

PRP is a fixed-ratio combination of pancreatic proenzymes trypsinogen and chymotrypsinogen, administered once weekly by intravenous injection. The company says the therapy works by inducing differentiation of malignant cells rather than directly killing them or blocking a single signaling pathway. Propanc claims PRP is non-cytotoxic and targets cancer stem cells and epithelial-mesenchymal transition, a process associated with cancer spread and treatment resistance.

In preclinical models of pancreatic

Propanc Biopharma plans Phase 1b trial for cancer drug PRP

Wed, 12 Aug 2026 08:32:26 -0400

In preclinical models of pancreatic

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Wed, 12 Aug 2026 08:30:00 -0400

Contrasting Science with Revolution Medicines and Erasca

MELBOURNE, Australia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today provided a scientific comparison of its lead candidate PRP with the RAS-targeted approaches of Revolution Medicines, Inc. and Erasca, Inc. The Company articulates why PRP’s unique mechanism—promoting cancer cell differentiation, reversing epithelial-mesenchymal transition (EMT), and targeting cancer stem cells via pancreatic proenzymes—positions it as a potential long-term therapy of choice, particularly for aggressive, treatment-resistant cancers such as pancreatic

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Wed, 12 Aug 2026 08:30:00 -0400

Contrasting Science with Revolution Medicines and Erasca

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Wed, 12 Aug 2026 08:30:00 -0400

Contrasting Science with Revolution Medicines and Erasca

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Wed, 12 Aug 2026 08:30:00 -0400

Contrasting Science with Revolution Medicines and Erasca

Propanc reports 90%+ tumor growth inhibition for PRP in pancreatic cancer

Thu, 06 Aug 2026 08:31:40 -0400

Propanc Biopharma, Inc. (Nasdaq: PPCB) announced preclinical and translational data for its lead drug candidate PRP in pancreatic ductal adenocarcinoma (PDAC), according to a company press release.

In orthotopic and patient-derived xenograft models of advanced PDAC, intravenous PRP administered three times weekly produced greater than 90% mean tumor growth inhibition compared with vehicle controls (p < 0.001). Treated animals showed a median overall survival extension of more than 2.5-fold versus controls, along with a reduction in metastatic burden in the liver and peritoneum.

The data also indicated remodeling of the tumor microenvironment, including decreased cancer-associated fibroblast activity and reduced fibrosis. PRP appeared

Propanc reports 90%+ tumor growth inhibition for PRP in pancreatic cancer

Thu, 06 Aug 2026 08:31:40 -0400

Propanc Biopharma, Inc. (Nasdaq: PPCB) announced preclinical and translational data for its lead drug candidate PRP in pancreatic ductal adenocarcinoma (PDAC), according to a company press release.

The data also indicated remodeling of the tumor microenvironment, including decreased cancer-associated fibroblast activity and reduced fibrosis. PRP appeared

Propanc Biopharma reports preclinical data showing 90% tumor inhibition

Thu, 06 Aug 2026 08:31:27 -0400

Propanc Biopharma, Inc. (NASDAQ: PPCB) announced preclinical and translational data for its lead drug candidate PRP in pancreatic ductal adenocarcinoma (PDAC), according to a company press release.

In orthotopic and patient-derived xenograft models of advanced PDAC, intravenous PRP administered three times weekly showed greater than 90% mean tumor growth inhibition compared with vehicle controls (p < 0.001). Treated animals showed a median overall survival extension of more than 2.5-fold compared with controls.

Additional findings included a reduction in metastatic burden in the liver and peritoneum, remodeling of the tumor microenvironment, and enhanced sensitivity of chemo-resistant PDAC cells to gemcitabine/nab-paclitaxel at lower doses.

PRP

Propanc Biopharma reports preclinical data showing 90% tumor inhibition

Thu, 06 Aug 2026 08:31:27 -0400

Propanc Biopharma, Inc. (NASDAQ: PPCB) announced preclinical and translational data for its lead drug candidate PRP in pancreatic ductal adenocarcinoma (PDAC), according to a company press release.

PRP

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

Thu, 06 Aug 2026 08:30:00 -0400

Accelerates Phase 1b First-in-Human Trial Timeline

MELBOURNE, Australia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced compelling new preclinical and translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and treatment-resistant solid tumors.